AC Immune SA (NASDAQ:ACIU) Sees Significant Growth in Short Interest

AC Immune SA (NASDAQ:ACIU - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,350,000 shares, an increase of 23.9% from the February 28th total of 1,090,000 shares. Based on an average daily volume of 182,400 shares, the days-to-cover ratio is presently 7.4 days. Approximately 2.2% of the shares of the company are sold short.

AC Immune Stock Down 6.2 %

Shares of NASDAQ:ACIU traded down $0.11 during midday trading on Friday, reaching $1.66. The company's stock had a trading volume of 249,225 shares, compared to its average volume of 329,605. The stock has a fifty day moving average of $2.39 and a 200 day moving average of $2.86. AC Immune has a twelve month low of $1.64 and a twelve month high of $4.98. The firm has a market capitalization of $166.68 million, a PE ratio of -3.61 and a beta of 1.49.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of AC Immune in a research note on Thursday.

Hedge Funds Weigh In On AC Immune

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in AC Immune by 6.4% during the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock worth $220,000 after acquiring an additional 3,499 shares during the period. RPO LLC purchased a new stake in AC Immune in the 4th quarter worth approximately $51,000. Renaissance Technologies LLC boosted its position in AC Immune by 14.6% in the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company's stock worth $1,999,000 after purchasing an additional 94,191 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new stake in shares of AC Immune during the 4th quarter worth approximately $27,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of AC Immune by 130.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock valued at $355,000 after purchasing an additional 74,358 shares during the period. Hedge funds and other institutional investors own 51.36% of the company's stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.